Biden Could Shake Up Higher Ed If He Doesn’t Endorse the Status Quo
Now that President Biden has been sworn in as the 46th president, he wants to hit the ground running and attend to urgent priorities. One of his first moves was to extend student loan payment deferrals until October, buying time for further reforms to America’s higher education system.
Deferrals will be one small part of a larger strategy to shift higher education costs away from borrowers and toward taxpayers, regardless of cost and consequences. Rather than creating a bank-breaking new strategy to subsidize (predominately) well-off graduates, President Biden should offer low-income students better alternatives to the broken status quo.
Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host a series of virtual Research & Development events in 2021, with the first one scheduled for Monday, January 25, 2021, 11 a.m. to 1 p.m. ET.
The first event will focus on Passage Bio’s lead investigational therapy PBGM01 and its disease target, infantile GM1 gangliosidosis (GM1). Presenters for the event are:
Bruce Goldsmith, Ph.D., chief executive officer, who will present an overview of the Passage Bio pipeline and the GM1 disease and patient experience.
Posted on 123
Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that President and CEO, Usman “Oz” Azam, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:10 pm ET.
A live webcast of the presentation will be available on the “Events and Presentations” page of the Tmunity website at https://www.tmunity.com/events. Tmunity will maintain an archived replay of the webcast on the website for 30 days after the conference.
About Tmunity Therapeutics
Tmunity is a private, clinical-stage biotherapeutics company, focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with th
- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program - - Patient enrollment in UK clinical study site expected to start in the second quarter of 2021 -
According to the Centers for Disease Control and Prevention (CDC), opioid overdoses killed more than 46,000 people in 2018. Even in the midst of the global COVID-19 pandemic, opioid addiction remains a serious public health issue throughout the United States.
Students in a Rutgers University–Camden biology class are working to better understand the neuroscience related to this crisis, thanks to an innovative program that allows them to conduct research from home.
“People are struggling with addiction and the loss of loved ones,” says Nathan Fried, a Rutgers University‒Camden assistant teaching professor of biology. “It has touched personally each and every one of us.”